Wendt A G, Jones S E, Salmon S E
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):269-73.
We analyzed the efficacy of salvage therapy with systemic agents in 33 women who initially received adjuvant chemotherapy with Adriamycin and cyclophosphamide (AC) for early breast cancer. Relapses occurred at a median of 9 months after completion of adjuvant therapy, and six patients relapsed while receiving adjuvant treatment. Nonetheless, salvage treatment produced objective responses in three of ten patients (30%) receiving hormonal therapy alone, in five of 11 (45%) receiving AC plus hormonal therapy, and in none of 12 receiving cyclophosphamide, methotrexate, and 5-fluorouracil (P < 0.05). Survival from the time of relapse from adjuvant chemotherapy was superior for patients receiving hormonal therapy with or without AC chemotherapy compared to that of patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil (P < 0.05), and the median survival time of responders is > 12 months. On the basis of these findings, we believe that patients relapsing after adjuvant chemotherapy should receive aggressive treatment employing Adriamycin combination chemotherapy along with hormonal therapy.
我们分析了33例最初接受阿霉素和环磷酰胺（AC）辅助化疗的早期乳腺癌女性患者采用全身药物进行挽救性治疗的疗效。辅助治疗完成后，复发的中位时间为9个月，6例患者在接受辅助治疗时复发。尽管如此，在接受单纯激素治疗的10例患者中，有3例（30%）获得客观缓解；在接受AC加激素治疗的11例患者中，有5例（45%）获得客观缓解；而在接受环磷酰胺、甲氨蝶呤和5-氟尿嘧啶治疗的12例患者中无一例获得客观缓解（P<0.05）。与接受环磷酰胺、甲氨蝶呤和5-氟尿嘧啶治疗的患者相比，接受激素治疗联合或不联合AC化疗的患者从辅助化疗复发时起的生存期更长（P<0.05），缓解者的中位生存时间>12个月。基于这些发现，我们认为辅助化疗后复发的患者应接受采用阿霉素联合化疗及激素治疗的积极治疗。
